Lantus (Insulin Glargine): Tracking Guide

Insulin glargine -- sold as Lantus (and its follow-on products Basaglar and Semglee) -- is a long-acting basal insulin used to manage blood sugar in type 1 and type 2 diabetes. It is injected subcutaneously once daily and provides a near-peakless insulin baseline for approximately 24 hours. Among all injectable medications, daily insulin may be the one where tracking discipline has the most direct, measurable impact on health outcomes.

Quick Reference -- Lantus (Insulin Glargine)

Detail	Value
Generic name	Insulin glargine
Drug class	Long-acting basal insulin analog
Route	Subcutaneous (SubQ) only
Delivery	SoloStar pen, KwikPen, or 10 mL vial with syringe
Concentration	100 units/mL (U-100); Toujeo is 300 units/mL (U-300)
Dosing frequency	Once daily, same time each day
Injection sites	Abdomen, thigh, upper arm
Storage (in use)	Room temperature, up to 28 days
Storage (unopened)	Refrigerate 2-8 degrees C
Duration of action	~24 hours (up to 30+ hours at higher doses)
Critical rule	Rotate sites to prevent lipohypertrophy

What It Is

Insulin glargine is a synthetic insulin analog. It differs from human insulin by two amino acid modifications: asparagine at position A21 is replaced with glycine, and two arginine residues are added to the C-terminus of the B chain. These changes shift the molecule's isoelectric point to a neutral pH, which causes it to form microprecipitates when injected into the subcutaneous tissue (which has a physiologic pH of about 7.4).

Those microprecipitates are the key to the drug's long action. Instead of dissolving rapidly like regular insulin, insulin glargine slowly dissolves from these tiny crystalline deposits, releasing insulin into the bloodstream at a steady, predictable rate over approximately 24 hours.

Insulin glargine is clear, not cloudy. Unlike NPH insulin, which is a suspension that requires mixing before injection, glargine is a solution. If it looks cloudy or has particles, do not use it.

FDA-approved for:

• Type 1 diabetes -- as basal insulin in a basal-bolus regimen (always used alongside rapid-acting mealtime insulin)
• Type 2 diabetes -- as basal insulin, often added when oral medications alone cannot maintain glycemic targets

Lantus (by Sanofi) was the original brand. Biosimilar and follow-on products include Basaglar (Lilly) and Semglee (Viatris). All contain insulin glargine U-100 and are clinically interchangeable. Toujeo (Sanofi) is a concentrated formulation (U-300) with a slightly different pharmacokinetic profile -- longer duration, flatter curve -- and is not unit-for-unit interchangeable with U-100 products.

How It Works

In a person without diabetes, the pancreas secretes a low, continuous level of insulin between meals and overnight -- basal insulin. This background insulin keeps the liver from overproducing glucose and maintains blood sugar in a stable range even when you are not eating.

In type 1 diabetes, the pancreas produces no insulin at all. In type 2 diabetes, insulin production may be reduced, and the body's cells may be resistant to the insulin that is produced. In both cases, injected basal insulin fills the gap.

Insulin glargine mimics the basal insulin output of a healthy pancreas. After subcutaneous injection, the microprecipitates dissolve gradually, releasing insulin glargine into surrounding capillaries. Once in the bloodstream, it is metabolized into active metabolites (M1 and M2) that bind to insulin receptors on muscle, fat, and liver cells, promoting glucose uptake and suppressing hepatic glucose output.

The pharmacokinetic profile is relatively flat -- there is no pronounced peak, which reduces the risk of hypoglycemia compared to older basal insulins like NPH. Most of the glucose-lowering activity occurs evenly across the 24-hour period, with a slight tail-off toward the end.

Basal insulin does not cover meals. Insulin glargine provides a background insulin level. Patients with type 1 diabetes and some with type 2 diabetes also need rapid-acting insulin (like lispro or aspart) to cover carbohydrate intake at meals. Understanding this distinction prevents dosing errors.

Dosing

Insulin glargine dosing is highly individualized. There is no single "standard dose" -- the right dose is the one that brings your fasting blood glucose into your target range without causing hypoglycemia.

Type 2 diabetes (initial):

• Starting dose is typically 10 units once daily, or 0.1-0.2 units/kg/day
• Dose is titrated (adjusted) every 3-7 days based on fasting blood glucose
• Common titration: increase by 2 units every 3 days until fasting glucose is in target range

Type 1 diabetes:

• Basal insulin typically represents 40-50% of total daily insulin dose
• The remainder is covered by mealtime (bolus) insulin
• Dose adjustments are based on fasting glucose, continuous glucose monitoring (CGM) data, and carbohydrate counting

Titration targets (common):

These are general guidelines. Your prescriber will set specific targets based on your age, comorbidities, hypoglycemia risk, and treatment goals.

Titration requires data. You cannot adjust your insulin dose accurately without consistent blood glucose readings, especially fasting values. Log every morning's reading alongside your injection time and dose. The pattern over 3-7 days -- not a single reading -- drives the adjustment decision.

Injection Sites

Insulin glargine is a subcutaneous injection only. Never inject it intravenously -- this can cause severe hypoglycemia.

Approved injection sites:

Absorption varies by site. The abdomen generally provides the fastest and most consistent absorption. For basal insulin, the difference between sites is less clinically significant than for rapid-acting insulin, but consistency matters. Pick a general area (e.g., abdomen) and rotate within it, or rotate systematically between areas on a predictable schedule.

Site Rotation and Lipohypertrophy

This is the most important injection technique issue for anyone on long-term daily insulin. Lipohypertrophy -- hardened, lumpy, or rubbery areas of fatty tissue that develop from repeated injection into the same spot -- is extremely common among insulin users. Studies report prevalence rates of 30-60%.

Lipohypertrophy is not just cosmetic. It directly impairs insulin absorption. Injecting into a lipohypertrophic area produces erratic, unpredictable blood sugar readings -- sometimes the insulin absorbs slowly, sometimes barely at all, sometimes it releases in an unexpected bolus hours later. If your blood sugar swings despite consistent dosing, check your injection sites.

How to rotate properly:

• Divide each injection area into quadrants or zones.
• Move to a new zone with each injection, following a clockwise or grid pattern.
• Stay at least 1 inch (2.5 cm) from any previous injection spot.
• Do not return to the same zone for at least 1-2 weeks.
• Inspect injection areas monthly by pressing gently -- lipohypertrophic tissue feels firmer or lumpier than surrounding fat.

Example 7-day abdomen rotation:

If you discover lipohypertrophic areas, avoid them entirely and let them heal -- which can take months. You may need a dose reduction when switching to healthy tissue, because absorption will be more efficient.

Pen injection technique:

1. Attach a new pen needle (4-5 mm, 32 gauge for most adults).
2. Prime the pen: dial 2 units and press the injection button until insulin appears at the needle tip. This ensures the needle is clear.
3. Dial your prescribed dose.
4. Insert the needle at 90 degrees into a pinched fold of skin (or straight in without pinching, depending on needle length and body composition).
5. Press the injection button all the way down.
6. Hold for 10 seconds before withdrawing -- this allows the full dose to be delivered and prevents insulin from leaking out.
7. Remove the needle and dispose of it in a sharps container. Do not reuse pen needles.

Side Effects

The primary risk of insulin therapy is hypoglycemia. Other side effects are generally less serious but worth tracking.

Common side effects:

• Hypoglycemia (low blood sugar) -- the most common and most dangerous side effect. Symptoms: shakiness, sweating, hunger, confusion, rapid heartbeat, dizziness. Severe hypoglycemia can cause loss of consciousness and seizure.
• Injection site reactions -- redness, swelling, itching (uncommon with modern analogs)
• Lipohypertrophy -- from poor site rotation (see above)
• Weight gain -- insulin is an anabolic hormone; modest weight gain is common when starting or increasing doses
• Peripheral edema -- mild fluid retention, especially early in treatment

Serious side effects (seek immediate help):

• Severe hypoglycemia -- confusion, inability to swallow, loss of consciousness, seizure. Treat with glucagon injection if the patient cannot eat. Call emergency services.
• Hypokalemia -- insulin drives potassium into cells; significant drops can cause cardiac arrhythmia (rare with basal insulin alone, more relevant with IV insulin)
• Severe allergic reaction -- rash over entire body, difficulty breathing, rapid heartbeat (very rare)

Every insulin user should have a hypoglycemia action plan. Know the symptoms, keep fast-acting glucose (glucose tablets, juice) accessible at all times, and ensure that someone close to you knows how to administer glucagon. Log every hypoglycemic event -- frequency, severity, timing, and possible cause.

What to Monitor

Diabetes management is data-intensive. The more consistently you track, the better your outcomes.

Clinical monitoring:

Daily self-monitoring:

• Fasting blood glucose -- every morning, before injection (this is the primary data point for basal insulin titration)
• Pre-meal and post-meal glucose -- if also on mealtime insulin or if prescribed by your clinician
• CGM data -- if you use a continuous glucose monitor, review time-in-range, overnight trends, and glucose variability
• Hypoglycemic events -- time, severity, what you ate, what you did to treat it
• Injection site -- which area, which zone within the area

Tracking Your Insulin Glargine

Daily medication is harder to track than weekly medication in one specific way: the sheer volume of data points. Over a month, you generate 30 injection records, 30+ blood glucose readings, and potentially hundreds of CGM data points. Without a system, this data does not exist in any useful form.

What to log for every injection:

• Date and time -- consistency of timing is a core part of the regimen
• Dose in units
• Injection site and zone (e.g., right upper abdomen, left thigh)
• Pen or vial -- and when the pen was first opened (28-day use limit)
• Pen needle -- new needle used? (reuse degrades sharpness and increases lipohypertrophy risk)
• Fasting blood glucose that morning

Also track on an ongoing basis:

• Blood glucose readings -- fasting, pre-meal, post-meal, bedtime (as prescribed)
• Hypoglycemic events -- with time, severity, suspected cause, treatment
• HbA1c results -- plot the trend over time
• Weight -- weekly or biweekly
• Dose changes -- date, old dose, new dose, reason
• Pen inventory -- pens in the fridge, current pen open date, pens remaining

This tracking directly drives clinical decisions. Your prescriber adjusts your dose based on fasting glucose trends. Your endocrinologist evaluates treatment efficacy by HbA1c trajectory. Your diabetes educator assesses injection technique by site rotation patterns and hypoglycemia frequency. Without data, these conversations are guesswork.

For more on choosing a tracking tool, see our best medication tracker app guide.

Frequently Asked Questions

What time of day should I take Lantus?

Lantus can be taken at any time of day, but it must be taken at the same time every day. Many patients inject at bedtime, though morning dosing is equally valid. Consistency of timing is more important than the specific hour.

Why is site rotation important for insulin glargine?

Injecting into the same spot repeatedly causes lipohypertrophy -- hardened, lumpy fatty tissue under the skin. Lipohypertrophy impairs insulin absorption, leading to unpredictable blood sugar levels. Rotating within and between injection areas prevents this.

Can I mix Lantus with other insulins?

No. Lantus must not be mixed with any other insulin or diluted. Its unique pH (approximately 4.0) is what creates the microprecipitate that provides the long-acting effect. Mixing alters the pH and destroys the mechanism.

How should I store my Lantus pen?

Unopened pens: refrigerate at 2-8 degrees C (36-46 degrees F), do not freeze. Once in use: store at room temperature (up to 30 degrees C / 86 degrees F) for up to 28 days. After 28 days, discard the pen even if insulin remains.

What happens if I miss a dose of Lantus?

If you miss a dose, take it as soon as you remember. If it is close to your next scheduled dose, consult your prescriber -- do not double the dose. Missed basal insulin doses cause blood sugar to rise gradually over 12-24 hours. Track every dose to prevent this.

Sources

1. Lantus (insulin glargine) - FDA Prescribing Information -- U.S. Food and Drug Administration
2. Insulin Glargine: A Review of Its Therapeutic Use as a Long-Acting Agent -- Drugs
3. Lipohypertrophy: Prevalence, Risk Factors, and Clinical Impact -- Diabetes Research and Clinical Practice
4. ADA Standards of Care in Diabetes -- Pharmacologic Approaches to Glycemic Treatment -- Diabetes Care (American Diabetes Association)
5. Best Practices for Insulin Injection Technique -- World Journal of Diabetes

Done Dose handles the daily complexity of insulin management -- one-tap dose logging, automatic site rotation tracking, fasting glucose recording, pen expiration countdowns, and a complete history your endocrinologist can review in seconds. Stop losing data to memory and start building the record that drives better A1c results. Start tracking your insulin glargine with Done Dose.